Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31results about How to "Suitable treatment" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oral pharmaceutical formulations for antidiabetic compounds
InactiveUS20100087481A1Improve solubilitySurprising chemical stabilityBiocideAntipyreticDiseaseEnergy homeostasis
Oral pharmaceutical preparations of salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. The oral pharmaceutical preparation is useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.
Owner:LEE KATHLEEN M
Preventives/remedies for organ functional disorders and organ dysfunction
InactiveUS20040204500A1Increasing ubiquinoneAvoid dysfunctionBiocideNervous disorderFunctional disturbanceOrgan dysfunction
The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
Owner:TAKEDA PHARMA CO LTD
Novel heterocyclic compounds
InactiveUS20160376277A1Prevention and treatmentSuitable preventionBiocideNervous disorderEnantiomerBruton's tyrosine kinase
The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors.
Owner:CADILA HEALTHCARE LTD
High-density lipoprotein-cholesterol level elevating agent
InactiveUS20040063750A1Satisfying effect for preventionHigh density lipoproteinBiocideOrganic chemistryMedicinal chemistrySqualene Synthetase
A novel high-density lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.
Owner:TAKEDA PHARMA CO LTD
Benzophenones as inhibitors of reverse transcriptase
InactiveUS7273863B1Suitable preventionSuitable treatmentBiocideOrganic chemistryMedicineReverse transcriptase
The present invention includes benzophenone compounds (I)which are useful in the treatment of HIV infections.
Owner:SMITHKLINE BECKMAN CORP +1
Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor
InactiveUS20100099881A1Inhibitory activitySuitable preventionNervous disorderOrganic chemistryHydrogenMedicinal chemistry
An object of the invention is to provide a novel sphingosine compound with an inhibitory activity against sphingomyelinase, and a method for producing the sphingosine compound.The novel sphingosine compound or a salt thereof according to the invention is represented by Formula (1):wherein one of R1 and R2 is hydrogen, and the other is a group represented by Formula (G):wherein n is 0 or 1; and R3 is hydrogen, C1-23 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C1-6 alkoxy, C3-8 cycloalkyloxy, phenyl, or furil.
Owner:GLYTECH
Lipopeptides for Use in Treating Liver Diseases and Cardiovascular Diseases
ActiveUS20160015775A1Avoid enteringPromote digestionUltrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsLiver diseasePeptide
The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and / or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and / or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and / or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and / or treatment of a cardiovascular disease.
Owner:UNIVERSITY OF HEIDELBERG
Heterocyclic compounds
InactiveUS9840509B2Prevention and treatmentSuitable preventionNervous disorderOrganic chemistryEnantiomerBruton's tyrosine kinase
The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors.
Owner:CADILA HEALTHCARE LTD
Wound dressing
Provided is a further improved wound dressing suitable for a method for treating a wound while maintaining a moist environment created by exudate oozing from the wound. The wound dressing (5) comprises at least three layers including a first layer, a second layer and a third layer in order from the side used in contact with a wound site, which layers are integrally stacked together. The first layer (1) comprises a resin sheet material having a number of pores penetrating in a thickness direction. The second layer (2) comprises a sheet material of which the surface is water-repellent and becomes water-permeable when pressure is applied. The third layer (3) comprises a sheet material capable of absorbing and holding water. The wound dressing optionally comprises a fourth layer comprising a resin film, a fabric or a nonwoven.
Owner:ZUIKO CORP
Benzophenones as inhibitors of reverse transcriptase
InactiveUS20060009651A1Suitable preventionSuitable treatmentOrganic active ingredientsAntiviralsReverse transcriptaseBenzophenone
The present invention is directed to benzophenone compounds useful in the inhibition of HIV reverse transcriptase, particularly its resistant varieties.
Owner:CHAN JOSEPH
Pharmaceutical composition for preventing and treating diabetic nephropaphy including adenosine derivative
ActiveUS11266644B2Preventing or treating diabetic nephropathyPrevention and treatment of diabetic nephropathyUrinary disorderPharmaceutical non-active ingredientsNephrosisAdenosine
Owner:FUTURE MEDICINE CO LTD
Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor
InactiveUS8093395B2Suitable preventionSuitable treatmentBiocideNervous disorderMedicinal chemistrySphingosine
Owner:GLYTECH
Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
InactiveUS20070072910A1Decrease plasma levelIncrease in plasma levelBiocideAnimal repellantsVery low-density lipoproteinNiacin
The present invention is directed to compositions and method to lower the plasma concentration of a low density lipoprotein in a human. One aspect is the invention is directed to compositions comprising at least one pharmaceutically acceptable L-carnitine compound and at least one pharmaceutically acceptable niacin compound, in such amount as to reduce the concentration of a low density lipoprotein. Another embodiment is directed to a composition of L-carnitine and niacin that substantially reduces side-effects associated with niacin treatment. Another aspect of the invention relates to a method for treating hyperlipidemia while substantially reducing side-effects associated with niacin treatment by administering a composition of L-carnitine and niacin.
Owner:NEXGEN PHARMA
Methods for Preventing or Treating Bone Disorders
ActiveUS20080131521A1Suitable preventionSuitable treatmentBiocideTetrapeptide ingredientsPeptideLipid metabolism
The present invention relates to a method of preventing or treating a bone disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a peptide having ability to modulate lipid metabolism but having no appreciable effect on IGF-1.
Owner:METABOLIC PHARMA LTD
Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
ActiveUS11185556B2Promote absorptionSmall toxicityPowder deliverySenses disorderAdenosinePharmaceutical medicine
A pharmaceutical composition for preventing or treating eye diseases and an oral administration agent for preventing or treating eye diseases are provided. The pharmaceutical composition for preventing or treating eye diseases comprises the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Owner:FUTURE MEDICINE CO LTD
Pyrazole carboxamide derivatives, pharmaceutical compositions and its preparation
Owner:BEIJING MOLECULE SCI & TECH
Pharmaceutical composition comprising pancreatin and a lipase-containing coating
PendingUS20200121766A1Increase blockingImproved therapyPeptide/protein ingredientsDigestive systemPharmaceutical SubstancesOrganic chemistry
The present invention relates to a pharmaceutical composition comprising pancreatin, which has a coating that contains a least one lipase. Preferably the at least one lipase is burlulipase. It also relates to a medicinal product comprising such a pharmaceutical composition. A method of producing such a pharmaceutical composition also forms part of the present invention.
Owner:NORDMARK PHARMA GMBH
Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
PendingUS20220025019A1Reduce usageUseful in treatmentPowder deliverySpray deliveryDiseaseObstructive Pulmonary Diseases
This invention is in the field of preventing or treating acute exacerbations in chronic lung diseases, such as chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis, by administration of polyclonal immunoglobulin to the respiratory tract, in particular by direct application of an aerosolized composition comprising polyclonal immunoglobulin.
Owner:CSL BEHRING AG
Phenolic acid derivative compound and use thereof
ActiveUS10696623B2Skin whiteningSuitable for useCosmetic preparationsOrganic chemistryTyrosinePharmaceutical drug
The present invention relates to a novel phenolic acid derivative compound with whitening and antioxidant activities and use thereof. The phenolic acid derivative compound is a compound represented by Formula 1, which is described in the specification, an isomer thereof or a salt thereof. The compound of the present invention has skin whitening activity to inhibit tyrosinase, thus being suitable for use in a pharmaceutical composition or cosmetic product for skin whitening. In addition, the compound of the present invention is suitable for the prevention or treatment of oxidation-derived skin abnormality or disease such as skin aging due to its antioxidant activity.
Owner:DAEBONG LS CO LTD
Novel phenolic acid derivative compound and use thereof
ActiveUS20180362448A1Suitable for useSuitable preventionCosmetic preparationsOrganic chemistryDiseaseTyrosinase
The present invention relates to a novel phenolic acid derivative compound with whitening and antioxidant activities and use thereof. The phenolic acid derivative compound is a compound represented by Formula 1, which is described in the specification, an isomer thereof or a salt thereof. The compound of the present invention has skin whitening activity to inhibit tyrosinase, thus being suitable for use in a pharmaceutical composition or cosmetic product for skin whitening. In addition, the compound of the present invention is suitable for the prevention or treatment of oxidation-derived skin abnormality or disease such as skin aging due to its antioxidant activity.
Owner:DAEBONG LS CO LTD
Pharmaceutical composition for preventing and treating diabetic nephropaphy including adenosine derivative
ActiveUS20200289511A1Preventing or treating diabetic nephropathyPrevention and treatment of diabetic nephropathyOrganic active ingredientsPharmaceutical delivery mechanismNephrosisAdenosine
A pharmaceutical composition for preventing or treating diabetic nephropathy is provided. According to the present invention, a pharmaceutical composition for preventing or treating diabetic nephropathy comprises an adenosine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient.
Owner:FUTURE MEDICINE CO LTD
Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use
InactiveUS20080293780A1Suitable preventionSuitable treatmentBiocideNervous disorderGlucose utilizationDisease
The present invention comprises bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, their functional derivatives thereof as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below,wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
![Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use](https://images-eureka.patsnap.com/patent_img/2d893c00-aa9b-491d-8601-a764b132ab78/US20080293780A1-20081127-C00001.png "Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use")
![Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use](https://images-eureka.patsnap.com/patent_img/2d893c00-aa9b-491d-8601-a764b132ab78/US20080293780A1-20081127-C00002.png "Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use")
![Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use](https://images-eureka.patsnap.com/patent_img/2d893c00-aa9b-491d-8601-a764b132ab78/US20080293780A1-20081127-C00003.png "Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use")
Owner:SANOFI SA
Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative
ActiveUS20200016186A1Suitable preventionPromote absorptionPowder deliverySenses disorderOral medicationAdenosine
A pharmaceutical composition for preventing or treating eye diseases and an oral administration agent for preventing or treating eye diseases are provided. The pharmaceutical composition for preventing or treating eye diseases comprises the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
Owner:FUTURE MEDICINE CO LTD
Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
ActiveUS11179453B2Reduced reactogenicityImprove effectivenessBacterial antigen ingredientsSsRNA viruses positive-senseHepatitis B immunizationAdjuvant
An immunogenic composition comprising of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen, Hepatitis B surface antigen (HBsAg), inactivated whole-cell B. pertussis (wP) antigen, Haemophilus influenzae type B (Hib) capsular saccharide conjugated to a carrier protein, Inactivated Polio Virus (IPV) antigen and additionally one or more antigens and the method of preparing the same. A fully liquid combination vaccine, showing improved immunogenicity, reduced reactogenicity and improved stability. Improved methods of formaldehyde inactivation, improved adsorption profile of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen and Hepatitis B (HepB) surface antigen adsorbed individually onto aluminium phosphate adjuvant, minimum total aluminum content (Al3+) and optimized concentration of 2-phenoxyethanol (2-PE) as preservative.
Owner:SERUM INST OF INDIA PTE LTD
Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives
ActiveUS11266650B2Alleviating nonalcoholic steatohepatitisAbsorbed excellentlyDigestive systemPharmaceutical non-active ingredientsAdenosineHepatic fibrosis
A pharmaceutical composition for preventing or treating liver disease is provided. The pharmaceutical composition comprising a compound represented by formula 1 below or a pharmaceutically acceptable salt of the compound as an active ingredient:where A is S, R is a linear or branched C1-C5 alkyl which is non-substituted or is independently or selectively substituted with one or more C6-C10 aryl groups, a benzyl which is non-substituted or is independently or selectively substituted with halogen or one or more linear or branched C1-C4 alkoxy groups, or a hydroxycarbonyl-substituted benzyl, and Y is H or a halogen atom.
Owner:FUTURE MEDICINE CO LTD
Methods for preventing or treating bone disorders
InactiveUS8008433B2Suitable preventionSuitable treatmentBiocidePeptide/protein ingredientsDiseasePharmacology
The present invention relates to a method of preventing or treating a bone disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a peptide having ability to modulate lipid metabolism but having no appreciable effect on IGF-1.
Owner:METABOLIC PHARMA LTD
Pyrazole carboxamide derivatives, pharmaceutical compositions and its preparation
A compound of formula (I) or pharmaceutically acceptable salts and / or solvates or hydrates thereof. A process for preparing the compound, a pharmaceutical composition comprising the compound and an application for resisting cannabinoid CB1 receptor are provided.
Owner:BEIJING MOLECULE SCI & TECH
Lipopeptides for use in treating liver diseases and cardiovascular diseases
ActiveUS10413585B2Avoid enteringPromote digestionCompound screeningOrganic active ingredientsAssayCholesterol uptake
The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and / or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and / or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and / or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and / or treatment of a cardiovascular disease.
Owner:UNIVERSITY OF HEIDELBERG
Dicaffeoyl spermidine cyclized derivatives and use thereof
ActiveUS10457702B2Improve cognitive functionSuitable preventionOrganic active ingredientsNervous disorderPositive controlDrug biological activity
Owner:JINAN UNIVERSITY
Agent for preventing or treating organ functional disorders and organ dysfunction
InactiveUS20060241096A1Suppressing of progressImprove insulin resistanceBiocideOrganic active ingredientsOrgan dysfunctionObesity
The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
Owner:SUGIYAMA YASUO +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com